Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14ClNO2S |
| Molecular Weight | 307.795 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl
InChI
InChIKey=DCASRSISIKYPDD-AWEZNQCLSA-N
InChI=1S/C15H14ClNO2S/c16-12-4-2-1-3-11(12)14(15(18)19)17-7-5-13-10(9-17)6-8-20-13/h1-4,6,8,14H,5,7,9H2,(H,18,19)/t14-/m0/s1
| Molecular Formula | C15H14ClNO2S |
| Molecular Weight | 307.795 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterization of degradation products of amorphous and polymorphic forms of clopidogrel bisulphate under solid state stress conditions. | 2010-07-08 |
|
| Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. | 2010-04 |
|
| Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. | 2010-03-03 |
|
| Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. | 2010-02-01 |
|
| Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. | 2010 |
|
| Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. | 2009-12 |
|
| Late-onset erythromelalgia in a previously healthy young woman: a case report and review of the literature. | 2009-11-04 |
|
| A validated enantiospecific method for determination and purity assay of clopridogrel. | 2009-11 |
|
| Effect of sample preparation method on quantification of polymorphs using PXRD. | 2009-10-22 |
|
| Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. | 2009-10 |
|
| Use of aspirin versus clopidogrel plus aspirin after coronary artery bypass graft surgery. | 2009-10 |
|
| Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. | 2009-09 |
|
| Clopidogrel/aspirin combination therapy in high-risk atrial fibrillation patients. | 2009-07-04 |
|
| Antiplatelet drugs and the perioperative period: What every urologist needs to know. | 2009-07 |
|
| Treatment for blunt cerebrovascular injuries: equivalence of anticoagulation and antiplatelet agents. | 2009-07 |
|
| Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. | 2009-06-10 |
|
| Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? | 2009-05-06 |
|
| Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit? | 2009-03-20 |
|
| Quantifying low levels of polymorphic impurity in clopidogrel bisulphate by vibrational spectroscopy and chemometrics. | 2009-01-15 |
|
| Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. | 2009-01 |
|
| [Bleeding and thromboembolic risk. Perioperative strategy in aspirin/clopidogrel]. | 2009 |
|
| Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma. | 2008-11-15 |
|
| In situ monitoring of polymorph transformation of clopidogrel hydrogen sulfate using measurement of ultrasonic velocity. | 2008-10 |
|
| [Effect of nattokinase on restenosis after percutaneous transluminal angioplasty of the abdominal artery in rabbits]. | 2008-08 |
|
| The single individual in medicine: how to escape from the probability theory trap. | 2008-07-24 |
|
| Percutaneous heartworm removal from dogs with severe heart worm (Dirofilaria immitis) infestation. | 2008-06 |
|
| Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. | 2008-04 |
|
| Evidence for prolonged prescribing of aspirin-clopidogrel combination in Scottish primary care. | 2008-04 |
|
| Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs. | 2008-03-13 |
|
| Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. | 2008-02-15 |
|
| Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy? | 2008-02 |
|
| Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. | 2008-01-28 |
|
| Platelet aggregation and recruitment with aspirin-clopidogrel therapy. | 2008 |
|
| To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment. | 2007-11 |
|
| Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. | 2007-11 |
|
| Utilisation review of clopidogrel: are they used under the FDA-approved indications? | 2007-09 |
|
| Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. | 2007-08-29 |
|
| [Modified platelet aggregation test in patients on ASA and/or clopidogrel]. | 2007-08 |
|
| Con: continuation of aspirin/clopidogrel for cardiac surgery. | 2007-08 |
|
| Pro: continuation of aspirin/clopidogrel for cardiac surgery. | 2007-08 |
|
| Evidence-based use of medications in patients with coronary artery disease in a rural Australian community. | 2007-08 |
|
| [Interindividual variability in the laboratory response to the aspirin-clopidogrel combination: are patients with stent occlusion "resistant" to treatment?]. | 2007-05 |
|
| A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. | 2007-05 |
|
| Quality assessment of platelet rich plasma during anti-platelet therapy. | 2007-01 |
|
| Management of atrial fibrillation. | 2007 |
|
| Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. | 2007 |
|
| Chemometric simultaneous estimation of clopidogrel bisulphate and aspirin from combined dosage form. | 2006-11-07 |
|
| Risk factor awareness and secondary prevention of coronary artery disease: are we doing enough? | 2006-06 |
|
| Stability indicating HPTLC determination of clopidogrel bisulphate as bulk drug and in pharmaceutical dosage form. | 2003-12-04 |
|
| Aspirin "failures," clopidogrel added to aspirin, and secondary stroke prevention in veterans presenting with TIA or mild-to-moderate ischemic stroke. | 2003-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:08 GMT 2025
by
admin
on
Mon Mar 31 18:01:08 GMT 2025
|
| Record UNII |
1B9Z4634CD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
144457-28-3
Created by
admin on Mon Mar 31 18:01:08 GMT 2025 , Edited by admin on Mon Mar 31 18:01:08 GMT 2025
|
PRIMARY | |||
|
1B9Z4634CD
Created by
admin on Mon Mar 31 18:01:08 GMT 2025 , Edited by admin on Mon Mar 31 18:01:08 GMT 2025
|
PRIMARY | |||
|
DTXSID10891466
Created by
admin on Mon Mar 31 18:01:08 GMT 2025 , Edited by admin on Mon Mar 31 18:01:08 GMT 2025
|
PRIMARY | |||
|
9861403
Created by
admin on Mon Mar 31 18:01:08 GMT 2025 , Edited by admin on Mon Mar 31 18:01:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
RACEMATE -> ENANTIOMER |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
